drugset / Trial / NCT00189241

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

NCT00189241

Phase 3 Completed 160 enrolled MEDA Pharma GmbH & Co. KG
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term sustained clearance rate of superficial basal cell carcinoma during a 5 year period following treatment with imiquimod

Timeline

Start
2001-02
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 5 % Topical

Indications